Yesterday, I wanted to cook stuffed artichokes for dinner. So, I searched Google for a video and found this on YouTube: "ITALIAN STUFFED ARTICHOKES - SICILIAN STYLE - EASTER DINER RECIPE."
Before the cooking lesson started, there was an in-video ad for an Rx drug, the name of which I can't recall right now. No matter. After 15 seconds or so I realized I could click on "Skip Ad" and not hear any more of the side effects, aka FDA-required Important Safety Information (ISI), "major statement," and "Fair Balance" stuff that is usually crammed into Direct-to-Consumer (DTC) TV ads after about 20 or 30 seconds.
Ruth Day of Duke University once said of print and TV DTC drug ads (here): “Risk information is physically present but functionally absent.” This accurately describes what's happening in skippable in-video DTC ads on Youtube.
According to YouTube Help, there are two versions of in-video ads: (1) skippable ads like the one I saw, and (2) non-skippable ads.
It seems that pharma uses only the former, not the latter. Is this acceptable?
Read more »
Showing posts with label fair balance. Show all posts
Showing posts with label fair balance. Show all posts
Wednesday, 11 November 2015
Friday, 13 February 2015
DTC Print Ads Need Consumer-Friendly Fair Balance Information
The FDA recently published revised draft guidance on "Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements." (see "Disclosing Risk in DTC Print Ads: Introducing the 'Consumer Brief Summary'").
The brief summary is the part of direct-to-consumer (DTC) ads that conveys detailed risk information. Typically, this information appears on the back side of the print ad and is sometimes written in small type.
In the original guidance published in 2004, FDA suggested a "less is more" approach (see “FDA Draft Guidance for Print DTCA: Less than Feared”). At that time, FDA said it "believes that exhaustive lists of minor risks detract from and make it difficult to comprehend and retain information on the more important risks." In the revised guidance, FDA suggests specific, more readable formats for the brief summary. As shown in the example below, some DTC print ads have already used these formats in the brief summary section of the ad.
What no one is talking about, however, is the "fair balance" section of the ad. Let's look at a typical Rx drug print ad.
Read more »
The brief summary is the part of direct-to-consumer (DTC) ads that conveys detailed risk information. Typically, this information appears on the back side of the print ad and is sometimes written in small type.
In the original guidance published in 2004, FDA suggested a "less is more" approach (see “FDA Draft Guidance for Print DTCA: Less than Feared”). At that time, FDA said it "believes that exhaustive lists of minor risks detract from and make it difficult to comprehend and retain information on the more important risks." In the revised guidance, FDA suggests specific, more readable formats for the brief summary. As shown in the example below, some DTC print ads have already used these formats in the brief summary section of the ad.
What no one is talking about, however, is the "fair balance" section of the ad. Let's look at a typical Rx drug print ad.
Read more »
Subscribe to:
Posts (Atom)
